Doximity faces flat growth, competitive pressure, and overvaluation, making it a potential short with a $45 target. Click ...

Doximity DOCS reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 38 cents, which beat the Zacks ...

Doximity saw increased retail buzz on Thursday following its fourth-quarter (Q4) earnings report, which displayed strong ...

Doximity's Q4 performance likely witnessed strong product ... holding steady at $58. However, the stock is beating the S&P 500’s 6.2% decline during that period. Doximity (DOCS) concluded ...

Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Jeff Tangney, ...

Revenue Growth: Over the 3M period, Doximity showcased positive performance ... defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company ...

In light of the recent options history for Doximity, it's now appropriate to focus on the company itself. We aim to explore its current performance ... suggest the stock is currently may be ...

The stock is significantly overvalued ... to the detriment of shareholders. Doximity's favourable financial performance is likely to persist due to its growth in strategic areas like deepening ...

Doximity DOCS reported fourth-quarter fiscal ... shares of DOCS plunged 20.7% during after-hours trading on May 15. The stock fell 9.5% year to date compared with a 6.2% decline in the industry.

Doximity reported fourth-quarter fiscal 2025 ... shares of DOCS plunged 20.7% during after-hours trading on May 15. The stock fell 9.5% year to date compared with a 6.2% decline in the industry.